Abstract
We have recently reported about shorter proteolytic peptides termed Catalytide as general name. JAL-TA9 (YKGSGFRMI), a fragment peptide derived from Box A region of Tob1 protein, is the first Catalytide and cleaves Aβ42 and its fragment peptides.Herein, we demonstrate the enzymatic properties of ANA-TA9 corresponding region to JAL-TA9 in ANA/BTG3 protein. ANA-TA9 showed the auto-proteolytic activity and cleaved 3 kinds of synthetic fragment peptides derived from Aβ42, especially on the central region of Aβ42 with a serine protease like activity. Interestingly, 2 kinds of components, ANA-SA5 (SKGQA) and ANA-YA4 (YRMI), also showed similar proteolytic activity. These results indicate that ANA-TA9 is composed of two different Catalytides.
Highlights
According to recent reports, Tob/BTG family proteins display antiproliferative activity in a variety of cell types and are involved in the regulation of tumorigenesis [1, 2, 3, 4, 5, 6, 7, 8]
We focus on ANA-TA9 (SKGQAYRMI) derived from Box A region of the ANA/BTG3 protein corresponding to JAL-TA9 to find new Catalytide
Three kinds fragment peptides derived from the Box A region of the ANA/BTG3 protein and 3 kinds of Aβ-fragment peptides were synthesized
Summary
Tob/BTG family proteins display antiproliferative activity in a variety of cell types and are involved in the regulation of tumorigenesis [1, 2, 3, 4, 5, 6, 7, 8]. To the best of our knowledge, protease-like activity has never been reported in the Tob/BTG family of proteins or in small synthetic peptides. We have previously found the auto-proteolytic activity and the proteolytic activity of the synthetic nona-peptide JAL-TA9 (YKGSGFRMI) derived from the Box A region of the Tob protein against Aβ42 and its fragment peptides, Aβ1-20 and Aβ11-29 [9, 10, 11, 12, 13]. We reported the similar proteolytic activity of 5-mer synthetic peptides derived from JAL-TA9 [15]. The proteolytic activity of JAL-TA9 suggests that Tob/BTG family proteins may possess the proteolytic activity
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
